BPI 2241
Alternative Names: BPI-2241Latest Information Update: 18 Feb 2022
At a glance
- Originator Beta Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 18 Feb 2022 Preclinical trials in Solid tumours in USA (unspecified route) as of February 2022 (Beta Pharma website, February 2022)
- 04 Aug 2021 BPI 2241 is available for licensing as of 04 Aug 2021. http://betapharma.com/about-us/oncology-drug-development/
- 04 Aug 2021 Early research in Solid tumours in USA (unspecified route) (Beta Pharma pipeline, August 2021)